文献速递心律失常血脂与心血管预防

达比加群两种剂量对房颤卒中与大出血的个体化疗效估计

Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
PubMed 文献 · Circulation · 2019-05-03

模型区分度尚可,c-statistic分别为0.65和0.69。达比加群150mg每日两次的5年缺血性卒中/系统性栓塞绝对风险降低在不同患者间差异很大,高剂量与低剂量比较的净获益仅在46%患者中为正。

要点

  • 基于常规临床特征可估计达比加群个体绝对获益与风险。
  • 高剂量达比加群5年卒中绝对风险降低在不同患者间差异显著。
  • 高剂量较低剂量的净获益仅在46%患者中为正。

核心结论

  • 房颤患者达比加群的绝对治疗获益与危害可基于易获取的患者特征进行估计,可用于共享决策和确定最佳剂量。

主要发现

  • 模型校准良好,缺血性卒中/系统性栓塞的c-statistic为0.65(95%CI 0.62-0.70),大出血为0.69(95%CI 0.66-0.71)。
  • 达比加群150mg每日两次的5年缺血性卒中/系统性栓塞绝对风险降低在20%患者中<10%,在14%患者中>25%。
  • 5年大出血绝对风险增加在53%患者中<5%,在1%患者中为15%至20%。
  • 高剂量较低剂量的净获益(绝对风险降低减绝对风险增加)在46%患者中为正。

临床怎么用

  • 治疗效应估计可用于开始达比加群治疗前的共享决策,并帮助确定最佳剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to estimate absolute benefit and harm from treatment with dabigatran in individual patients with atrial fibrillation, and to select the optimal dose for each individual. METHODS: We derived and validated a prediction model for ischemic stroke/systemic embolism and major bleeding in patients with atrial fibrillation from the 3 treatment arms of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy With Dabigatran Etexilate) (n=11 955 in derivation cohort, n=6158 in validation cohort). Readily available patient characteristics were included in Fine and Gray competing risk models (sex, age, smoking, antiplatelet drugs, previous vascular disease, diabetes mellitus, blood pressure, estimated glomerular filtration rate, and hemoglobin). Five-year risks for ischemic stroke/systemic embolism and major bleeding were estimated without anticoagulation therapy, and compared with high- and low-dose dabigatran. RESULTS: Model calibration was good, and discrimination was adequate with a c-statistic of 0.65 (95% CI, 0.62-0.70) for ischemic stroke/systemic embolism and 0.69 (95% CI, 0.66-0.71) for major bleeding. The 5-year absolute risk reduction for ischemic stroke/systemic embolism with dabigatran 150 mg twice daily ranged from <10% in 20% of patients to >25% in 14% of patients, and the 5-year absolute risk increase for major bleeding ranged from <5% in 53% of patients to 15% to 20% in 1% of patients. Comparing high-dose to low-dose dabigatran, the net benefit (absolute risk reduction minus absolute risk increase) was positive for 46% of patients. CONCLUSIONS: The absolute treatment benefits and harms of dabigatran in atrial fibrillation can be estimated based on readily available patient characteristics. Such treatment effect estimations can be used for shared decision making before starting dabigatran treatment and to determine the optimal dose. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00262600.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Stam-Slob MC, Connolly SJ, van der Graaf Y, et al. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019. PMID: 31046423. doi:10.1161/CIRCULATIONAHA.118.035266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。